This page contains brief information about idelalisib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
|US Brand Name(s):||Zydelig|
Idelalisib is approved to be used alone or with other drugs to treat:
- Chronic lymphocytic leukemia (CLL) that has recurred (come back). It is used with rituximab in patients who are able to be treated with rituximab alone.
- Non-Hodgkin lymphoma (NHL) that has recurred (come back). It is used in patients who have already received at least two systemic treatments. It is used in the following types of NHL--
Idelalisib is also being studied in the treatment of other types of cancer.More About Idelalisib
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.Research Results
Clinical Trial Results: Combination of Idelalisib and Rituximab Improves Survival in Patients with Relapsed Chronic Lymphocytic Leukemia - Important clinical trial results for this drug, background information, and how the trial was done.Clinical Trials Accepting Patients
Find Clinical Trials for Idelalisib - Check for trials from NCI's list of cancer clinical trials now accepting patients.
Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.